“We are seeing a growing international awareness and demand not only for regenerative and functional medicine, but also integrative personalised medicine in general. Each of us is different because of variations in genetics, environmental factors and lifestyle choices – so the “one size fits all” approach is not always optimal. Conventional medicine is quite good at addressing the symptoms of illness and disease once they occur, but it isn’t great at identifying the root cause of problems at an early stage and preventing disease,” said Julian Andriesz, founder and CEO of Verita Healthcare Group.

Verita Healthcare Group offers an integrative approach to oncology care through its Verita Life clinics. Verita Life complements the three mainstream approaches of chemotherapy, radiation therapy and surgery by supporting the patient in areas such as medically supervised detoxification and immune system enhancement. Their specialists also offer noninvasive treatment options and guidance on diet and nutrition.

“Our programs help to minimise adverse side effects and rebuild immunity faster to improve overall outcomes and quality of life. We also have programs for patients with a high genetic predisposition to cancer and those in remission from cancer,” said Andriesz. Verita Health offers an approach to anti-ageing combines scientific breakthroughs in biological age screening, genetics, regenerative therapies and product innovations from around the world under one roof from scientists and doctors that specialise in longevity medicine. The clinic’s approach is not about absence of disease, says Andriesz, but having optimal functionality and enhanced wellbeing via a customised program and personalised service. Verita Healthcare Group will be launching what it describes as one of the most “advanced life extension and human enhancement centres in the world” in Bangkok. The centre, to be located in the city’s iconic Mahanakhon development, is expected to open in the third quarter of this year.

In November 2015, Verita Healthcare Group announced it has signed an agreement with Lionstar Technologies Pte Ltd to be the authorised distributor of its breakthrough Metabolic Testing Energy Service (METS) systems in 11 countries in the Asia Pacific region. “It is one of many innovative technologies and devices that Verita Healthcare offers. ETS have developed technology, know how and associated business systems to identify, diagnose and manage human energy disorders such as obesity (energy surplus), fatigue (energy deficit) and diabetes (energy production). ETS and the parent group Lionstar Technologies Pte, have taken a standard research technology Indirect Calorimetry and developed a simple system for practitioners and retail use,” said Andriesz.

Singapore, 25 April 2016 – Verita Healthcare Group (“Verita”) has signed a licensing agreement with Auswell Limited and Acpharm HK Limited to commence clinical trials for the implementation of the Naltrexone time released medication in the China market.

Naltrexone is an opioid receptor antagonist. The primary indications for the use of Naltrexone are the management of opioid and alcohol addiction. Verita Research Pte Ltd has the unique delivery dose system, a controlled release depot that releases therapeutic levels of Naltrexone for a period of time makes the hospitalization period shorter and compliance much simpler as the patient isn’t faced with the daily decision of whether to take their dose of naltrexone or break out. The specialized formulation delivers Naltrexone at therapeutic levels for up to 30 days. The number of registered addicts in 2004 was 1.14 million (more than 75% of them heroin addicts), but the actual number is probably far higher. China faces substantial drug abuse problems that appear to be worsening with time. Opiate dependence is a major threat to the public health and social security of China because of its devastating medical effects, its impact on risk for HIV/AIDS and criminal behaviors, low rates of recovery and high rates of relapse. There is an urgent need to implement modern treatments for opiate dependence more widely in China. Comments: “Naltrexone time released delivery medication is a proven, safe and effective treatment to be used in the fight against opiate addiction in China”

Singapore, 4 January 2016 – Verita Healthcare Group (Verita), through its wholly owned subsidiary Verita Biotech Ltd, has acquired a 51% equity stake in MRG & Associates Ltd owner of a global patent portfolio for Mechano Growth Factor (MGF) which covers both cardiac and muscle use which has the potential to be developed into a marketable and effective drug for skeletal muscle wastage and cardiac muscle damage.

The MGF patent portfolio owned by MRG & Associates has been valued independently by BDO UK at 40.0 million pounds sterling.

BACKGROUND

Mechano Growth Factor was discovered and patented by Professor Goldspink who has held 7 professorial seats including UCL and Harvard. As part of his work he has studied muscle loss and wasting diseases based upon the common knowledge that young people’s muscles repair much more quickly than in the elderly.

Professor Goldspink has 3 dedicated decades of his life to the research of muscle wastage and related conditions. He believes that MGF has a wide application and continues to support its development into a long term viable muscular rebuilding and regeneration drug in other tissues.

Professor Goldspink’s team cloned the gene which is the product of a natural substance called IGF-I, a growth factor, which is then naturally “spliced” to yield 3 different types of proteins, one of which he called Mechano Growth Factor (MGF) as it is produced when cells are under mechanical strain and following tissue damage.
MGF was found to activate muscle stem cells to replicate and fuse with the existing muscle fibres needed for muscle repair.

There are a number of potential uses of MGF including:

(1) Skeletal muscle, with an application for conditions associated with muscle wasting such as muscular dystrophy and age-related sarcopenia. (Subject of a granted patent)

(2) Cardiac muscle, with the main potential being for conditions such as myocardial infarction. (Subject of a granted patent)

(3) Neuronal uses, with a potential repair application ( as yet, no patent in place)

The potential applications of MGF are significant. Preliminary indications and studies suggest that the use of MGF may assist in a number of ailments that are based on a deterioration of muscle or cardiac damage.

MGF is derived from the Insulin-like growth factor (IGF-I), which occurs naturally in the body, by alternative splicing. It was discovered that MGF kick-starts hypertrophy and starts the repair of local muscle damage by activating muscle stem cells.
In old age or certain diseases there is a marked loss in the ability to express MGF in which case the cells are not adequately replenished.

MGF is currently being used without licence by humans for performance enhancement including members of the body building community. It is however on the World Anti-doping Agency list of banned substances when administered as a peptide to increase muscle strength.

A primary interest in MGF lies in its use for cardiac patients. Tests have already been carried out on animals who have had myocardial infarctions and the MGF treated animals showed 35% less compromised muscle after 8 days.

Singapore, 4 January 2016 – AUSCUSTOM PHARMA SDN BHD is awarded EPP status from the Malaysian Ministry of Health to operate the largest GMP compounding pharmacy facility in SE ASIA. The project is the first (and only to date) GMP Compound Pharmacy project in Malaysia. The National Pharmaceutical Regulatory Agency views this facility to be the benchmark standard for the entire Compound Pharmaceutical industry in Malaysian.

The Economic Transformation Programme (ETP) in Malaysia was launched with 131 Entry Point Projects (EPPs). The National Key Economic Areas (NKEAs) are the engines of growth, while the Entry Point Projects are the spark plugs that will fire up these engines, to a new level of performance. They are called Entry Point Projects because these projects kick start the programme and they are not finite. These are high impact projects, matched with specific ideas and actions, to spur the growth of the NKEAs. Some involve large infrastructure investments while others have a more direct effect on the output of their sectors and on the life of Malaysians. These are all focussed on actions and not mere concepts.

Singapore, 30 June 2015 – Verita Healthcare Group (Verita) has acquired a 100% stake in Singapore-based Quantum Life Technologies, a regional product distribution company dealing in supplements, cosmeceuticals, nutraceuticals and medical devices.

QLT, which will eventually be renamed Verita Quantum Health, has the exclusive distribution rights for Asia Pacific for advanced liquid biopsy panels covering biological aging to the human microbiome and metabolism.

QLT is also exclusive distributor in Asia Pacific of ‘TimeBlock’ a unique botanical supplement product that has been proven to safely reverse biological aging in published human trials conducted at Vienna University.

The Company will act as a logistic & distribution service provider for Verita’s growing number of clinics and will also assist in the regional distribution of the groups other product ranges in the future.

Singapore, 30 June 2015 – Verita Healthcare Group (“Verita”) through its subsidiary Verita Research Pte Ltd, has acquired 100% of Australian Life Sciences Pty Ltd (“ALS”) located in Sydney, Australia is a Pharmaceutical Research and Development company that both develops proprietary drug technology and provides full service support for Product Research & Development to external clients.

The company has a highly qualified and experienced team of experts and is able to supply the industry with an extensive range of quality services. The full suite of services includes;

• Pre formulation Studies
• Formulation Studies
• Stability Studies
• Revamping Existing Products
• Small-Scale Manufacture
• Substantiation (test reporting) of Product Claims
• Clinical Trial Supply
• Marketing Services
• Graphic Design
• Novel Packaging Concepts
• Compilation of Documents

In addition to supplying services to external clients, ALS identifies specific product opportunities in the market and researches and develops proprietary products that are unique and overcome deficiencies in existing treatment modalities.

Singapore, 30 June 2015 – Verita Healthcare Group (“Verita”) has acquired 51% equity stake in Aus Cosmetics Pty Ltd (“Aus Cosmetics”).

Located in Sydney, Aus Cosmetics is a specialist GMP contract manufacturer of liquids, creams and serums for the medical cosmetic and skin care industry producing the highest quality products for premium clients within the Australian cosmetic and beauty industry.

Singapore, 30 March 2015 – Auscustom Pharma Sdn Bhd signs a 10 year lease for a 27,521 sq ft facility in I-PARK ISKANDAR to house the EPP awarded GMP compound pharmaceutical project.
Please refer “VERITA INNOVATE PTE LTD signs JV agreement to build the largest compound pharmaceutical manufacturer in SE ASIA”

Located in Kulaijaya, the thriving township of the future. I-Park@Indahpura is the ultimate clean and green industrial park that provides innovative solutions to fulfil your business needs. Comprising 104.84 acres of land, I-Park features semi-detached and detached factories with standard land sizes ranging from 19,966 sq.ft., 43,560 sql.ft., 87,120 sq.ft. and custom made sizes.
I-Park features a uniquely innovative clean and green concept that preserves the atmosphere and is environmentally friendly. Furthermore, I-Park also presents a green street concept in which lush landscaping and intelligently planned drainage systems optimizes the nature-friendly environment.

Singapore, 30 March 2015 – Verita Healthcare Group (“Verita”), through its wholly owned subsidiary Verita Innovate Pte Ltd, has signed a JV agreement with Australian Custom Pharmaceuticals Pty Ltd to establish a 51:49 compounding pharmacy facility in Iskandar Malaysia to be called Auscustom Pharma Sdn Bhd. Auscustom Pharma Sdn Bhd when completed will be the largest GMP Compound Pharmaceutical facility in SE Asia with a Pharmacy license capable of flexible and innovative production centered on a robust R&D approach.

Investment in a collaborative Research and Development strategy partnering with International and Local Universities/Institutes in development of medical solutions in the field of proteomics, integrative oncology and culturally sensitive (i.e. halal) health solutions.

The plant will be accredited with both Host nation (i.e. BPFK GMP) Licensing and Australian TGA GMP license specifically for the purpose of supplying Regional export markets (80%) and host country (up to 20%)

The plants range of core competencies will encompass sterile medications in prefilled syringe, cartridges, elastomeric pumps and EVA Bags through to Peptides and Oncology products.

Dissemination of world class IP employed exclusively in the production facility is at the heart of our Strategic differentiation

Australian Custom Pharmaceuticals Pty Ltd is an Integrative Manufacturer of Medicines and Preparations who for nearly 15 years have been developing and formulating innovative Dose Delivery Systems and catering for Medication shortages and Orphan Products in the Australian healthcare system.

Singapore 21 March 2014 – Verita Healthcare Group (Verita) opened its first integrative oncology clinic in Bangkok, Thailand the culmination of five years of international research with leading experts in immunology and integrative cancer care. The proprietary clinic which offers comprehensive evidence-based integrative cancer treatment programs has been designed to be fully scalable model so that it can be rolled-out internationally over time.

The clinic which caters for cancer patients from the Asia Pacific region as well as the local Thai market will also act as a regional research and training centre.

Verita Life offers supportive and complementary treatments for patients undergoing chemotherapy and radiation therapy who are interested to reduce negative side effects and rebuild their immune systems as well as offering help for those who have failed conventional approaches.